[go: up one dir, main page]

MXPA02010184A - Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia. - Google Patents

Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.

Info

Publication number
MXPA02010184A
MXPA02010184A MXPA02010184A MXPA02010184A MXPA02010184A MX PA02010184 A MXPA02010184 A MX PA02010184A MX PA02010184 A MXPA02010184 A MX PA02010184A MX PA02010184 A MXPA02010184 A MX PA02010184A MX PA02010184 A MXPA02010184 A MX PA02010184A
Authority
MX
Mexico
Prior art keywords
niacin
methods
transdermal delivery
topical formulations
treating hyperlipidemia
Prior art date
Application number
MXPA02010184A
Other languages
English (en)
Inventor
Of Kentucky Researc University
Original Assignee
Niadyne Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22730106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02010184(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Niadyne Corp filed Critical Niadyne Corp
Publication of MXPA02010184A publication Critical patent/MXPA02010184A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La niacina y profarmacos de niacina se administran topicamentecomo formulaciones o dispositivos adecuados para mejorar los perfiles deIipidos de sujetos, de preferencia humanos.
MXPA02010184A 2000-04-14 2001-04-16 Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia. MXPA02010184A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19762100P 2000-04-14 2000-04-14
PCT/US2001/012356 WO2001078727A1 (en) 2000-04-14 2001-04-16 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia

Publications (1)

Publication Number Publication Date
MXPA02010184A true MXPA02010184A (es) 2004-08-19

Family

ID=22730106

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010184A MXPA02010184A (es) 2000-04-14 2001-04-16 Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.

Country Status (13)

Country Link
US (1) US6677361B2 (es)
EP (1) EP1274429B1 (es)
JP (1) JP4156841B2 (es)
CN (1) CN1430513B (es)
AT (1) ATE395061T1 (es)
AU (2) AU2001257063B2 (es)
CA (1) CA2441461C (es)
DE (1) DE60134002D1 (es)
DK (1) DK1274429T3 (es)
ES (1) ES2302732T3 (es)
MX (1) MXPA02010184A (es)
PT (1) PT1274429E (es)
WO (1) WO2001078727A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof
US20040081672A1 (en) * 2002-10-25 2004-04-29 Gupta Shyam K. Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging
US20040191278A1 (en) * 2003-03-31 2004-09-30 Christensen Flemming Kjaergaar Topical agent for application to the skin prior to luminous treatment
US20040254202A1 (en) * 2003-06-13 2004-12-16 The Procter & Gamble Company Method of promoting sleep using topical administration of vasoactive agents
US20050267091A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
CN101742916B (zh) * 2007-02-28 2015-08-19 肯塔基大学研究基金会 减轻视黄酸治疗副作用和/或改进疗效而不干扰疗效的方法
WO2008126088A2 (en) * 2007-04-15 2008-10-23 Oron Zachar Anti-pyretic vasodilators
CN102532114B (zh) * 2011-12-19 2016-08-03 中山大学 烟酸衍生物,其制备方法及其药物组合物
EP3016655A4 (en) 2013-05-09 2017-04-12 Zeenar Enterprises Pty Ltd Niacin formulation
MX2016016071A (es) 2014-06-06 2017-07-11 Glaxosmithkline Intellectual Property (No 2) Ltd Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.
WO2019046735A1 (en) * 2017-08-31 2019-03-07 Lonza Inc. HEALTH PROMOTING COMPOSITION AND METHODS OF USING COMPLEMENT-RELATED APPLICATIONS
EP3727315B1 (en) 2017-12-18 2021-10-13 Unilever Global IP Limited A topical composition comprising n-cyclopropyl nicotinamide
US20200316050A1 (en) * 2017-12-18 2020-10-08 Conopco, Inc., D/B/A Unilever A topical composition based on niacinamide derivative
EP3873415A1 (en) 2018-11-02 2021-09-08 Unilever Global Ip Limited Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1046055B (de) * 1956-06-18 1958-12-11 Ernst Schneider Dipl Chem Dr Verfahren zur Herstellung eines Esters mehrfach ungesaettigter hoehermolekularer Fettsaeuren
EP0182635B1 (en) * 1984-11-15 1989-05-31 Nitto Denko Corporation Composition for percutaneous administration
GB2210789A (en) * 1987-10-10 1989-06-21 Morrison Dr Ian Donald Topical application for skin care
EP0346490B1 (en) * 1987-12-24 1993-04-07 Fujisawa Pharmaceutical Co., Ltd. Hair growth promoting agent
EP0643965B1 (en) * 1993-09-20 2013-05-08 Abbott Laboratories Nicotinic acid compositions for treating hyperlipidemia
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
EP0821587A4 (en) * 1995-04-19 1999-05-19 Lipoprotein Technologies Inc COMPOSITIONS, KITS AND METHODS FOR ADMINISTERING ANTILIPEMICS AND MEDICINES AGAINST PLATELET AGGREGATION
KR19990008242A (ko) * 1995-05-01 1999-01-25 까뜨리오나 프란세스 마르 니코틴산 에스테르 및 니코틴산 에스테르를 함유한 약품
GB9610971D0 (en) * 1996-05-29 1996-07-31 Scotia Holdings Plc A diagnostic test for use in schizophrenia
WO1998052927A1 (en) * 1997-05-19 1998-11-26 Rosemarie Scivoletto Composition for treating skin conditions
DK1143954T3 (da) * 1998-12-01 2004-12-20 Univ Kentucky Res Found Anvendelse af nicotinsyrederivater til behandling af DNA-skade i hudceller
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof

Also Published As

Publication number Publication date
CN1430513A (zh) 2003-07-16
WO2001078727A8 (en) 2003-11-27
JP4156841B2 (ja) 2008-09-24
CA2441461A1 (en) 2001-10-25
AU5706301A (en) 2001-10-30
US6677361B2 (en) 2004-01-13
US20010049382A1 (en) 2001-12-06
EP1274429A4 (en) 2006-03-01
EP1274429B1 (en) 2008-05-14
AU2001257063B2 (en) 2005-04-28
CA2441461C (en) 2007-07-10
EP1274429A1 (en) 2003-01-15
JP2004500428A (ja) 2004-01-08
CN1430513B (zh) 2010-12-08
WO2001078727A1 (en) 2001-10-25
ES2302732T3 (es) 2008-08-01
DK1274429T3 (da) 2008-08-25
ATE395061T1 (de) 2008-05-15
PT1274429E (pt) 2008-06-17
HK1053607A1 (en) 2003-10-31
DE60134002D1 (de) 2008-06-26

Similar Documents

Publication Publication Date Title
MXPA02010184A (es) Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
ATE365703T1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate,deren herstellung und anwendungen
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
MXPA02007915A (es) Mediador de lipido activado por aspirina.
PT2336184E (pt) Administração de agentes para o tratamento da inflamação
IL138509A0 (en) Topical transdermal anesthetic formulation
AU2002234525A1 (en) Transdermal therapeutic system comprising the active ingredient oxybutynin
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
EE05056B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
GB9521608D0 (en) Pharmaceutical composition
MXPA01011606A (es) Terapia anti-inflamatoria para infeccion mediada por inflamacion.
PT1150704E (pt) Melagatran para o tratamento da inflamacao
DE50104421D1 (de) Transportrolle
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
AR029451A1 (es) Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia
AU2001295979A1 (en) Medicinal compositions, dose and method for treating malaria
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
AU2002212489A1 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
FR2820423B1 (fr) Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie

Legal Events

Date Code Title Description
FG Grant or registration